Precision BioSciences (NASDAQ:DTIL) shares were up 10.3% during mid-day trading on Monday . The stock traded as high as $13.57 and last traded at $13.44. Approximately 687,652 shares traded hands during trading, an increase of 210% from the average daily volume of 221,734 shares. The stock had previously closed at $12.18.

Several research analysts have recently issued reports on DTIL shares. Barclays started coverage on Precision BioSciences in a research report on Monday. They set an “overweight” rating and a $24.00 price objective for the company. Goldman Sachs Group started coverage on Precision BioSciences in a research report on Monday. They set a “buy” rating and a $24.00 price objective for the company. JPMorgan Chase & Co. started coverage on Precision BioSciences in a research report on Monday. They set an “overweight” rating and a $23.00 price objective for the company. Finally, Jefferies Financial Group started coverage on Precision BioSciences in a research report on Monday. They set a “buy” rating for the company.

In other Precision BioSciences news, Director Tony Dung Ling Yao acquired 6,487 shares of the stock in a transaction dated Wednesday, April 3rd. The stock was acquired at an average cost of $15.42 per share, with a total value of $100,029.54. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Global Strategic Fund Venbio acquired 50,000 shares of the stock in a transaction dated Monday, April 1st. The shares were acquired at an average cost of $16.00 per share, with a total value of $800,000.00. The disclosure for this purchase can be found here.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.dailypolitical.com/2019/04/22/precision-biosciences-dtil-trading-up-10-3.html.

About Precision BioSciences (NASDAQ:DTIL)

Precision BioSciences, Inc operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities.

Further Reading: Asset Allocation, Balancing Your Investments

Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.